For Immediate Release:
Contact: Kelly Broadway, 202-808-8853
[email protected]
Washington, D.C. – The Council for Affordable Health Coverage (CAHC) welcomes efforts like TrumpRx that aim to improve prescription drug affordability and to provide greater transparency into drug prices.
High prescription costs remain a major challenge for many Americans, and tools that increase transparency and expand access to lower-cost options can be a constructive step forward.
We believe more action is needed. A recent Office of Inspector General (OIG) advisory opinion could have a chilling effect on TrumpRx by not allowing these discounts to be used by patients within their federal health plan coverage. For example, in Medicare, a senior using TrumpRx to pay for medications would not have these costs count toward their out-of-pocket maximum, even though they are clearly out-of-pocket expenses for the same prescription medicines.
Fixing this bureaucratic hurdle would significantly increase the uptake of TrumpRx for more than 150 million Americans who get their prescription medicines through a federal health care program.